The company said it has scaled up production capacity to two million reactions per week and has the potential to scale up to three million reactions per week.
The firms noted that QuantuMDx’s Capture-XT technology will enable downstream drug-susceptibility analysis, PCR, NGS, and, with this collaboration, nanopore detection.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The funding will be used to further develop a 20-minute tuberculosis detection assay and drug susceptibility test using the firm's handheld Q-POC microfluidic PCR system.
The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.
